The Latest Breaking News from MRNA

Moderna has underperformed the broader market and its peers over the past year, and Wall Street analysts are cautious about the stock’s prospects.

The S&P 500 Index ($SPX ) (SPY ) today is up +0.36%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.84%. Stocks today are moderately higher, with the S&P 500, the Dow Jones Industrials, and...

Moderna is expected to release its fiscal second-quarter earnings next month, and analysts project a narrower loss.

Moderna recently outperformed the S&P 500, and Wall Street analysts are moderately optimistic about the stock’s prospects.

With AI making waves in biotech, could this biotech’s OpenAI partnership be the catalyst for new highs?

Moderna has outperformed many of its peers and the broader market YTD, but Wall Street analysts are cautiously optimistic about the stock's prospects.

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

Moderna’s (MRNA) mRNA platform is positioned to deliver significant long-term impact with its mRNA medicines, but declining sales amid plummeting demand for its COVID-19 vaccine, steep losses, and cash burn reflect uncertainty around its near-term prospects. As MRNA is set to release its fourth-quarter 2023 results this Thursday, let’s find…

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).